To the Editors:
After early microbicide candidates failed in clinical trials to prevent HIV, recent news from the South African CAPRISA-004 study suggest that the new generation of vaginal microbicide gels using antiretroviral drugs like tenofovir could be effective and reduce HIV and herpes simplex virus-2 acquisition.1 This landmark study greatly energized the field and revived enthusiasm for the development of female-controlled products to prevent HIV acquisition in women, and if ongoing trials confirm the CAPRISA-004, results lead to a licensed product by 2014.2,3
Although the field is getting closer to identifying an effective compound against vaginal HIV transmission, significant challenges remain, such as a sustained coitally independent release of an effective drug and a product formulation and administration that suits life circumstances of women in developing countries. Stigma continues to limit women's access to HIV prevention strategies, and many women underestimate their own risk of HIV infection.4 Thus, a microbicide product perceived to improve overall vaginal health may decrease possible acceptability barriers that a single purpose product associated with HIV prevention may face.
In late May, the biannual global conference Microbicides 2010 held in Pittsburgh, PA, was attended by 1000 scientists and advocates, including more than 300 from Africa. The UCSF Bixby Center for Global Reproductive Health and the Consortium to Advance Multipurpose Innovations organized a Satellite Symposium titled “Probiotics: the Potential for a Live Microbicide”. The event provided a platform for researchers working in related fields to educate the conference audience and to initiate a discussion with other scientists, donors, advocates, members of federal agencies and world bodies, and regulatory experts to accelerate the development of probiotics for HIV prevention.
A handful of small biotechnology companies and academic groups are working to develop a new generation of genetically enhanced probiotics by inserting genes which code for potent antiviral compounds into bacteria that naturally colonize the vagina. Once administered to the vagina, these next generation probiotics have the potential to serve as a sustained, self-replicating delivery system for antimicrobial compounds to combat reproductive tract infections, including HIV. The potential advantages of a probiotic microbicide continuously producing anti-HIV protein compounds in situ over conventional microbicide delivery systems such as gels and films include (1) periodic, possibly weekly or monthly replenishment versus coitally dependent or daily dosing; (2) minimal disposal concerns, for example applicators; and (3) low risk of developing HIV resistance in comparison to antiretroviral therapy commonly used in treatment, such as tenofovir.
However, the field to date has been hampered by a relative lack of interest among donors due to competing HIV prevention technologies under development, lack of clarity regarding the regulatory pathway for licensure and general sensitivity surrounding genetically modified organisms (GMO), and financial fall-out from the recent worldwide recession.
PROBIOTIC MICROBICIDES FOR HIV PREVENTION
The normal vaginal environment is dominated by self-replicating lactobacilli species that maintain an acidic pH and inhibit the growth of pathogens and subsequent infections. Research of probiotic lactobacilli to improve genital health has increased steadily over the last 2 decades. The first generation of probiotics uses selected human strains for the prevention of recurrent bacterial vaginosis (BV) and urinary tract infection (UTI) following standard antibiotic treatment. Over time, researchers in this field have utilized new diagnostic technology such as rDNA polymerase chain reaction and improved product formulations and dosing regimens. Clinical trials have successfully demonstrated vaginal colonization with exogenous Lactobacillus strains and provided data on effectiveness against recurrent BV5-8 and UTI.9 Advances of these products will likely require testing of additional approaches, such as extending antibiotic treatment to more effectively destroy the bacterial biofilm and overcoming the negative influence of semen exposure10 and menstruation on the proportion of women colonized with the exogenous Lactobacillus strains.
The next generation of probiotics will be genetically engineered. Highly potent HIV inhibitors can be continuously produced by genetically enhanced self-renewing Lactobacillus bacteria that colonize the vaginal mucosa after periodical vaginal application.
The genetically modified Lactobacillus jensenii 1153-1666 (MucoCept) developed by Osel, Inc. follows this approach. Naturally occurring vaginal Lactobacillus strains were evaluated, and the L. jensenii 1153 was selected as the single best strain. Next, this strain was engineered to produce the potent HIV entry inhibitor Cyanovirin-N (CV-N). Last, Osel developed technology to preserve large quantities of MucoCept as a freeze-dried stable powder of pharmaceutical grade quality.
The further development of next generation probiotics will require extensive preclinical and early clinical testing before their efficacy can be tested. To be effective, these bacteria need to colonize the vagina in high concentrations in a large majority of women. In addition, the in situ protein expression and bioactivity and the immunological responses of the host need to be carefully monitored. Experiments in 20 Chinese rhesus macaques showed consistent lactobacilli colonization of CV-N-expressing L. jensenii for up to 90 days, at high levels of 105-107 colony-forming units (CFU) per swab.
In theory, because the CV-N protein is “foreign”, and the L. jensenii is not native to the macaque, an antibody response to either the CV-N or to the lactobacilli is possible, rendering the molecule inactive as a microbicide. During regular tests, using enzyme-linked immunosorbent assay in macaques exposed for more than 6 months, no antibody response to either the recombinant CV-N or to L. jensenii has been found in blood or cervicovaginal lavage samples (Dr. Qiang Xu, PhD, personal communication, 2010). Furthermore, the strain was easily cleared by topical administration of azithromycin.
In a repeated low-dose challenge model, Chinese rhesus macaques receiving MucoCept in comparison to controls had a 62% reduction in the rate of simian HIV acquisition (P = 0.037) (Dr. Laurel Lagenaur, PhD, personal communication, 2010). Next steps for the development of this product include a prephase 1 clinical trial of MucoCept to evaluate colonization, clearance after antibiotic treatment and biocontainment in a small group of healthy volunteers. In addition, Osel is exploring MucoCept as a platform to coexpress additional HIV inhibitors for as a multipurpose microbicide against HIV and other sexually transmitted infections (STIs).
Other groups of researchers are exploring similar concepts. ActoGenix, a Belgian company, is using genetically modified Lactococcus lactis, derived from the food industry, as a platform to deliver proteins such as the antiinflammatory cytokine Interleukin-10 to downregulate inflammatory bowel disease and ulcerative colitis. A L. lactis-producing Trefoil Factor 1 has been designed to prevent colitis11 and oral mucositis,12 a debilitating and painful side effect of radiotherapy and chemotherapy. Clinical phase 2 studies are under way for these products, and ActoGenix is also exploring L. lactis as a safe platform to deliver proinsulin to treat juvenile diabetes.
Due to the mixed perception and consideration of testing GMO in different regions of the world and to increase donor support to develop these products, the field needs to educate key stakeholders including the regulatory agencies around the world. The regulatory approval process for probiotic drugs faces unique challenges. First, in contrast to probiotic foods, pharmaceutical grade drugs need to be produced in facilities complying with Good Manufacturing Practices. Second, drugs that are deliberately releasing GMO need to follow country-specific guidelines addressing biocontainment and eradication. Third, regulatory agencies in different countries may have unique requirements that need to be sufficiently and proactively addressed when planning for and designing future clinical studies.
Although women in sub-Saharan Africa have the highest need for female-controlled HIV prevention technologies, women in other regions also require better prevention tools against HIV and other STIs. In tandem with the scientific development of these drugs, scientists and companies should concern themselves with the different contexts in which this technology may be introduced. End-user communities need to be involved from the beginning to create awareness and ensure their support and input for the clinical research and the eventual marketing and distribution. In addition to potential users, other gate keepers like their male partners, community leaders, and health care providers need to be engaged. Importantly, the daily realities of end-users such as storage, sanitary requirements, disposal options, and cost need to be considered to ensure that probiotic microbicides proven effective for HIV prevention will be used.
The CAPRISA-004 results restored enthusiasm for microbicides as a key technology to prevent HIV. To fulfill the promise of microbicides, research for additional antiretroviral compounds and delivery mechanisms needs to be stepped up. Women are waiting for safe, easy to use, inexpensive, and efficacious technologies to help them prevent HIV and other STIs. Probiotics, as a potential live microbicide, offer significant advantages including their safety profile, and a simplified self-replicating drug delivery platform. In addition, probiotics could serve as a component of multipurpose prevention tools for sexual and reproductive health to prevent multiple adverse health outcomes simultaneously, including HIV, STIs, unplanned pregnancy, and other reproductive tract infections such as BV.
As a new technology, the development of enhanced probiotics as HIV prevention drugs faces complex and unique challenges including competition for financial support, regulatory hurdles, manufacturing and logistical barriers, and effective branding and commercialization. To overcome these barriers, it is critical to forge multidisciplinary alliances of scientists, advocates, funders, government agencies, regulators, health care providers, and community of end-users. We will need to build strong alliances to create the momentum to successfully move live microbicides from the laboratory to the community.
We would like to thank the National Institutes of Health Office of AIDS Research for partial support and the UCSF/Gladstone Institute of Virology and Immunology Center for AIDS Research, the United States Agency for International Development, the UCSF Bixby Center for Global Reproductive Health, the Mary Wohlford Foundation, the Public Health Institute, and the Coalition for Advancement of Multipurpose Technology for their financial support of the symposium. In addition, we would like to acknowledge the other speakers including Samukeliso Dube, Laurel Lagenaur, Jeanne Marrazzo, Lothar Steidler, Jim A.Turpin, Qiang Xu, and Bethany Young Holt.
Anke Hemmerling, MD, PhD, MPH
Craig R. Cohen, MD, MPH
Bixby Center for Global Reproductive Health Department of Obstetrics, Gynecology and Reproductive Sciences University of California San Francisco San Francisco, CA
1. Karim QA, Karim SS, Frohlich JA, On behalf of the CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in Women. Science. 2010. Epub ahead of print.
5. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect. 2006;8:1450-1454.
6. Larsson PG. Stray-Pedersen B, Ryttig KR, et al. Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health. 2008;8:3.
7. Martinez RC, Franceschini SA, Patta MC, et al. Improved cure of bacterial vaginosis with single dose of tinidazole (2 g), Lactobacillus rhamnosus GR-1, and Lactobacillus reuteri RC-14: a randomized, double-blind, placebo-controlled trial. Can J Microbiol. 2009;55:133-138.
8. Mastromarino P, Macchia S, Meggiorini L, et al. Effectiveness of Lactobacillus-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. Clin Microbiol Infect. 2009;15:67-74.
9. Falagas ME, Betsi GI, Tokas T, et al. Probiotics for prevention of recurrent urinary tract infections in women: a review of the evidence from microbiological and clinical studies. Drugs. 2006;66:1253-1261.
10. Antonio MA, Meyn LA, Murray PJ, et al. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis. 2009;199:1506-1513.
11. Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology. 2004;127:502-513.
12. Caluwaerts S, Vandenbroucke K, Steidler L, et al. AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010;46:564-570.
© 2011 Lippincott Williams & Wilkins, Inc.